AST-3424
Modify Date: 2024-01-11 16:24:19
AST-3424 structure
|
Common Name | AST-3424 | ||
|---|---|---|---|---|
| CAS Number | 2097713-68-1 | Molecular Weight | 460.427 | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | C21H25N4O6P | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of AST-3424OBI-3424 (AST-3424, TH-3424) is a first-in-class, novel prodrug that selectively targets cancers overexpressing the enzyme AKR1C3, OBI-3424 is a highly selective prodrug that is converted by AKR1C3 to a DNA alkylating agent; OBI-3424 is a nitro-benzene prodrug of N,N’-bisethylenephosphoramidate, demonstrates in vivo efficacy against preclinical xenograft models of pediatric T-ALL. Liver Cancer Phase 2 Clinical |
| Name | OBI-3424 |
|---|
| Description | OBI-3424 (AST-3424, TH-3424) is a first-in-class, novel prodrug that selectively targets cancers overexpressing the enzyme AKR1C3, OBI-3424 is a highly selective prodrug that is converted by AKR1C3 to a DNA alkylating agent; OBI-3424 is a nitro-benzene prodrug of N,N’-bisethylenephosphoramidate, demonstrates in vivo efficacy against preclinical xenograft models of pediatric T-ALL. Liver Cancer Phase 2 Clinical |
|---|---|
| References | References 1. Richard B. Lock, et al. Abstract LB-B16: The AKR1C3-Activated Prodrug OBI-3424 Exerts Profound In Vivo Efficacy Against Preclinical Models of T-Cell Acute Lymphoblastic Leukemia (T-ALL); a Pediatric Preclinical Testing Consortium Study. AACR 2018. View Related Products by Target DNA Alkylator/Crosslinker Liver Cancer |
| Molecular Formula | C21H25N4O6P |
|---|---|
| Molecular Weight | 460.427 |